Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.41 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.41 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.41 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.41 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1790068 | 0.91 | CHEK2 (0.49) | CHEK2USP30CHRM3GPR119PDE4B | |
| SCHEMBL1790069 | 0.91 | CHEK2 (0.49) | CHEK2USP30CHRM3GPR119PDE4B | |
| SCHEMBL1785257 | 0.89 | GPR119 (0.54) | CHEK2GPR119PDE4B | |
| SCHEMBL21633309 | 0.87 | CHEK2 (0.44) | CHEK2USP30GPR119PDE4BPARP1 | |
| SCHEMBL5469410 | 0.87 | USP30 (0.47) | CHEK2USP30GPR119CACNB4CACNA1A | |
| SCHEMBL21723011 | 0.83 | USP30 (0.44) | USP30GPR119CACNB4CACNA1ACACNA1G | |
| SCHEMBL30272628 | 0.83 | USP30 (0.44) | USP30GPR119CACNB4CACNA1ACACNA1G | |
| SCHEMBL22462742 | 0.82 | GPR119 (0.48) | USP30GPR119CACNB4CACNA1ACACNA1G | |
| SCHEMBL21633347 | 0.82 | MAPT (0.42) | CHEK2USP30GPR119PDE4BPARP1 | |
| SCHEMBL22462879 | 0.81 | USP30 (0.45) | CHEK2USP30GPR119CACNB4CACNA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| CN-113302183-A | Cyclic ureas | 圣瑞诺有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-20130203730-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2013-08-08 | — | — | US | disclosed |
| EP-2607357-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2013-06-26 | — | — | EP | disclosed |
| US-20120115845-A1 | THERAPEUTIC AGENTS | ALLEN JACK MCQUEEN (GB) | 2012-05-10 | — | — | US | disclosed |
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| CN-101883762-A | Benzothiazoles as modulators of growth hormone releasing hormone receptors | ASTRAZENECA AB | 2010-11-10 | — | — | CN | disclosed |
| EP-2205576-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-07-14 | — | — | EP | disclosed |
| US-20090186870-A1 | Therapeutic Agents - 802 | ASTRAZENECA AB (SE) | 2009-07-23 | — | — | US | disclosed |
| WO-2009047558-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203730-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | GPR119, GHSR, GLP1R | CHEK2 4042/4885USP30 3802/4885CHRM3 512/4885 |
| US-20120115845-A1 | THERAPEUTIC AGENTS | GPR119, MC2R, MC4R | CHEK2 4695/4885USP30 4527/4885CHRM3 682/4885 |
| US-20090186870-A1 | Therapeutic Agents - 802 | GPR119, SLC5A2, MC2R | CHEK2 4278/4885USP30 3972/4885CHRM3 1071/4885 |
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | GPR119, GHSR, GLP1R | CHEK2 4042/4885USP30 3802/4885CHRM3 512/4885 |
| US-20210292305-A1 | Cyclic Ureas | RIPK1, RIPK3, RIPK4 | CHEK2 1052/4885USP30 221/4885CHRM3 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.